Argenx Takes Slow But Steady Approach To Vyvgart Sales
Amid Pandemic-Related And Educational Blocks
Despite a US approval for its novel FcRn inhibitor Vyvgart in gMG, the firm has realistic expectations of sales, factoring in concerns about COVID-19 and lagging medical education.
You may also be interested in...
The major has won US priority review for a commercially crucial label expansion of its breast cancer drug Enhertu while Tezspire and Ultomiris attracted positive CHMP opinions across the Atlantic.
With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.
Emerging Company Profile: Armed with the insight of its ex-Alexion leaders, Rallybio is eyeing a spate of deals to develop and commercialize transformative drugs for rare diseases.